7,554 Shares in Bristol Myers Squibb Company $BMY Purchased by Traub Capital Management LLC

Traub Capital Management LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, HoldingsChannel.com reports. The firm purchased 7,554 shares of the biopharmaceutical company’s stock, valued at approximately $350,000.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Crestwood Advisors Group LLC increased its holdings in shares of Bristol Myers Squibb by 38.4% during the first quarter. Crestwood Advisors Group LLC now owns 15,583 shares of the biopharmaceutical company’s stock worth $950,000 after purchasing an additional 4,326 shares during the period. Obermeyer Wealth Partners increased its holdings in shares of Bristol Myers Squibb by 28.5% during the first quarter. Obermeyer Wealth Partners now owns 13,090 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 2,904 shares during the period. Ignite Planners LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at approximately $380,000. Finally, Four Tree Island Advisory LLC grew its position in Bristol Myers Squibb by 28.6% during the first quarter. Four Tree Island Advisory LLC now owns 66,556 shares of the biopharmaceutical company’s stock worth $4,059,000 after buying an additional 14,783 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.6%

Shares of BMY opened at $47.09 on Wednesday. The stock has a market capitalization of $95.86 billion, a price-to-earnings ratio of 18.99, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The stock has a fifty day moving average of $45.34 and a 200-day moving average of $46.61.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Insider Activity

In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the subject of several analyst reports. Citigroup dropped their price objective on Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating for the company in a report on Monday. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Four analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $54.42.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.